Global Acne Market Analysis, 2014-2026: Key Pipeline & Marketed Drugs, Clinical Trials, Patent Information, 10-Year Prevalence Forecast, Licensing & Acquisition Deals, Revenue Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Acne (2020)” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Companies Mentioned

• Allergan
• Cassiopea
• Foamix
• GlaxoSmithKline
  

Key Takeaways

• The publisher estimates that in 2017, there were approximately 624 million prevalent cases of acne worldwide, and forecasts that number to increase to 683 million prevalent cases by 2026. Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes
• The majority of industry-sponsored drugs in active clinical development for acne are in Phase II, with only one drug in the NDA/BLA phase.
• Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.
• High-impact upcoming events for drugs in the acne space comprise topline Phase II trial results for FCD105 and an estimated PDUFA date for Winlevi/Breezula.
• The overall likelihood of approval of a Phase I dermatology-general asset is 25.2%, and the average probability a drug advances from Phase III is 75%. Drugs, on average, take 8.1 years from Phase I to approval in the dermatology-general space, as well as in the overall dermatology space.
• There have been 14 licensing and asset acquisition deals involving acne drugs during 2015-20. The largest deal was the $650m agreement in 2018 between Almirall and Allergan for the acquisition of a portfolio of five products from Allergan’s Medical Dermatology unit in the US, which comprises mature and growth brands Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide), and Seysara (sarecycline).
• The distribution of clinical trials across Phase I-IV indicates that the majority of trials for acne have been in the late phases of development, with 51.5% of trials in Phase III-IV, and 48.5% in Phase I-II.
• The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
• Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.
• GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for acne, followed by Allergan

Key Topics Covered

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

• Topical therapy
• Systemic therapy
• Physical treatments

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• Twyneo for Acne (December 30, 2019)
• ANT-1207 for Acne (June 25, 2019)
• VB 1953 for Acne (May 13, 2019)
• VB 1953 for Acne (May 13, 2019)
• Winlevi / Breezula for Acne (March 26, 2019)
• Aklief for Acne (February 22, 2019)
• Amzeeq for Acne (September 11, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

• Foamix Earns First Approval For Topical Minocycline With Amzeeq
• FDA Approves Aklief Cream for Acne Treatment
• Cassiopea Submits Acne Drug With New Mechanism Of Action
• Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

• Menlo And Foamix Merge Into Dermatology Play
• Deals Shaping The Medical Industry, November 2019
• Deals Shaping The Medical Industry, November 2019

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

• Sponsors By Status
• Sponsors By Phase

BIBLIOGRAPHY

• Prescription Information

APPENDIX

LIST OF FIGURES

Figure 1: Trends in prevalent cases of acne, 2017-26

Figure 2: Overview of pipeline drugs for acne in the US

Figure 3: Pipeline drugs for acne, by company

Figure 4: Pipeline drugs for acne, by drug type

Figure 5: Pipeline drugs for acne, by classification

Figure 6: Twyneo for Acne (December 30, 2019): Phase III – SGT-65-04, Phase III – SGT-65-05

Figure 7: VB 1953 for Acne (May 13, 2019): Phase II – Proof-of-Concept (ex. US)

Figure 8: VB 1953 for Acne (May 13, 2019): Phase I – First-In-Human

Figure 9: Winlevi / Breezula for Acne (March 26, 2019): Phase III – CB-03-01/27 (Long-Term Extension)

Figure 10: Aklief for Acne (February 22, 2019): Phase III – Perfect 1, Phase III – Perfect 2

Figure 11: Amzeeq for Acne (September 11, 2018): Phase III – FX2017-22

Figure 12: Key upcoming events in acne

Figure 13: Probability of success in the acne pipeline

Figure 14: Licensing and asset acquisition deals in acne, 2015-20

Figure 15: Parent patents in acne

Figure 16: Clinical trials in acne

Figure 17: Top 10 drugs for clinical trials in acne

Figure 18: Top 10 companies for clinical trials in acne

Figure 19: Trial locations in acne

Figure 20: Acne trials status

Figure 21: Acne trials sponsors, by phase

LIST OF TABLES

Table 1: Prevalent cases of acne, 2017-26

Table 2: Marketed drugs for acne

Table 3: Pipeline drugs for acne in the US

Table 4: Twyneo for Acne (December 30, 2019)

Table 5: ANT-1207 for Acne (June 25, 2019)

Table 6: VB 1953 for Acne (May 13, 2019)

Table 7: VB 1953 for Acne (May 13, 2019)

Table 8: Winlevi / Breezula for Acne (March 26, 2019)

Table 9: Aklief for Acne (February 22, 2019)

Table 10: Amzeeq for Acne (September 11, 2018)

Table 11: Historical global sales, by drug ($m), 2014-18

Table 12: Forecasted global sales, by drug ($m), 2020-23

For more information about this report visit https://www.researchandmarkets.com/r/b2vglg

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900